Streetbeat News

Stock Prices

GM

General Motors (GM) has projected its adjusted earnings per share (EPS) for 2024 to be between $8.50 and $9.50, surpassing the estimated $7.83.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 11:33 am

PHM

PulteGroup (NYSE:PHM) reported Q4 earnings per share (EPS) of $3.28, surpassing the analyst consensus estimate of $3.22. However, the company's quarterly sales of $4.29 billion fell short of the expected $4.48 billion. Compared to the same quarter last year, EPS decreased by 9.64%, and sales dropped by 16.97%.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 11:32 am

BK

Morgan Stanley analyst Betsy Graseck upgraded Bank of New York Mellon (NYSE:BK) from Underweight to Equal-Weight and increased the price target from $52 to $62.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 11:32 am

GM

General Motors (NYSE:GM) reported Q4 2023 earnings of $1.24 per share, surpassing the consensus estimate of $1.16. Quarterly sales were $43.00 billion, exceeding estimates of $38.97 billion but marking a slight 0.25% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 11:31 am

GM

General Motors (NYSE:GM) reported Q4 sales of $43.00 billion, surpassing the analyst consensus estimate of $38.97 billion by 10.34%. However, this represents a slight decrease of 0.25% from the $43.11 billion in sales reported in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 11:30 am

GILD

RCUS

Gilead Sciences Inc (GILD) has increased its investment in Arcus Biosciences Inc (RCUS) by $320 million at $21.00 per share, causing RCUS stock to soar. The investment and amended collaboration will accelerate the companies' joint cancer treatment programs, focusing on Phase 3 studies for lung and gastrointestinal cancers. Johanna Mercier of Gilead will join the Arcus Board. The additional funds extend Arcus's cash runway into 2027, supporting Phase 3 studies for pancreatic and kidney cancer treatments and preparation for potential product approvals. The ARC-10 study will be discontinued to prioritize the STAR-121 and STAR-221 studies, and the pancreatic cancer study will become an Arcus-independent study.

Portfolio Pulse from Vandana Singh

January 30, 2024 | 11:27 am

PHM

PulteGroup, Inc. has announced an increase of $1.5 billion to its share repurchase authorization, signaling confidence in the company's financial stability and a commitment to returning value to shareholders. This move could be seen as a positive sign by investors, as share buybacks often lead to an increase in earnings per share and can boost stock prices in the short term.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 11:26 am

OESX

Orion Energy Systems received a notice from Nasdaq on January 26 confirming that the company has regained compliance with the Nasdaq Bid Price Rule, according to an 8-K filing.

Portfolio Pulse from Charles Gross

January 30, 2024 | 11:19 am

HOPE

Hope Bancorp reported Q4 adjusted EPS of $0.32, surpassing the $0.21 estimate by 52.38%, but marking a 25.58% decrease from last year's $0.43 per share. Sales were $135.20M, falling short of the $138.35M estimate by 2.28% and down 16.87% from $162.63M in the prior year.

Portfolio Pulse from mahesh@benzinga.com

January 30, 2024 | 11:18 am

META

Meta Platforms Inc (NASDAQ:META) has partnered with the Center for Open Science to share 'privacy-preserving social media data' with researchers, ahead of a congressional hearing on children's online safety. The company, facing pressure to provide data for research on social media's mental health impact, expanded access through the Meta Content Library. CEO Mark Zuckerberg will testify before Congress, as Meta introduces new safety measures on Facebook and Instagram, including messaging restrictions and parental controls. META shares were up 0.47% premarket.

Portfolio Pulse from Anusuya Lahiri

January 30, 2024 | 11:17 am